Sutro Biopharma Inc
STROHealthcare·Biotechnology·USA·Micro·NASD·Nov 12 • 3:59 PM ET
9.59-0.67 (-6.53%)
2026-11-13 13:26 CET
Market cap
$159.01M
Revenue, TTM
45.11 USD m
Net income, TTM
-155.27 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-12.61
Price
STRO against its 20, 50 and 200-day averagesPatternshover a marker to name it
78.1% under the 52-week high of 43.85 on 15 May 2026. 52-week low 7.15 on 3 Dec 2025. Last 15 sessions, 32.8% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 2
CANSLIM 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: Debt/Equity: Low (<0.1); P/E: Under 25
Value 0 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15; P/B: Under 2; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 2 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
STRO52-week range, 7% of the way up
7.1543.85
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
| Index | RUT |
|---|---|
| Employees | 137 |
| IPO | Sep 27, 2018 |
| Beta | 1.54 |
| ATR, 14d | 0.95 |
| Rel volume | 0.00 |
| Short float | 15.71% |
| Insider own | 13.34% |
| Inst own | 93.19% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $159.01M |
| Enterprise Value | 275.84M |
| Income | -155.27M |
| Sales | 45.11M |
| Book / share | -6.23 |
| Cash / share | 8.57 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 137 |
| IPO | Sep 27, 2018 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 3.52 |
| Price / book | - |
| Price / cash | 1.12 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 6.11 |
| Quick Ratio | 3.32 |
| Current Ratio | 3.86 |
| Debt / equity | - |
| Long-term debt / equity | - |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -12.61 |
|---|---|
| Earnings next year | -6.33 |
| Earnings next quarter | -1.51 |
| Earnings this year | 64.48% |
| Earnings next year | 20.76% |
| Earnings growth, 5 years | 34.25% |
| Past earnings growth | 1.45% -17.92% |
| Past sales growth | 14.78% 19.12% |
| Earnings vs last year | 30.97% |
| Sales vs last year | -57.30% |
| Earnings vs last quarter | 71.66% |
| Sales vs last quarter | -6.14% |
| Earnings | Nov 12 AMC |
| Surprise | -15.80% -35.50% |
Ownership
| Insiders own | 13.34% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 93.19% |
| Institution trades | 6.78% |
| Return on assets | -80.39% |
| Return on equity | -1810.01% |
| Return on capital | -122.77% |
| Gross Margin | 87.88% |
| Operating margin | -254.72% |
| Profit Margin | -344.22% |
| 20-day average | -2.86% |
| 50-day average | -28.39% |
| 200-day average | -57.91% |
Technical
| Shares out | 16.58M |
|---|---|
| Shares floating | 14.37M |
| Short / float | 15.71% |
| Short ratio | 7.25 |
| Short interest | 2.26M |
| 52-week high | 43.85 -78.1% |
| 52-week low | 7.15 +34.1% |
| Volatility | 8.74% 9.03% |
| Average range | 0.95 |
| Strength index | 38.24 |
| Market sensitivity | 1.54 |
| Relative volume | 0.00 |
| Avg Volume | 311.35K |
| Volume | 0 |
Performance
| Perf Week | 4.24% |
|---|---|
| Perf Month | -8.84% |
| Perf Quarter | -53.17% |
| Perf Half Y | -75.04% |
| Perf YTD | -17.11% |
| Perf Year | 18.26% |
| Perf 3Y | -53.89% |
| Perf 5Y | -95.08% |
| Perf 10Y | - |
| Recommendation | 1.29 |
| Target Price | 47.31 |
| Prev Close | 9.59 |
| Price | 9.59 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 30, 2026 | Resumed | Wells Fargo | Overweight | $49 | +410.9% |
| Aug 07, 2026 | Initiated | Stifel | Buy | $48 | +400.5% |
| Jun 11, 2026 | Resumed | Truist | Buy | $50 | +421.4% |
| May 28, 2026 | Initiated | Barclays | Overweight | $56 | +483.9% |
| May 15, 2026 | Upgrade | Wedbush | Neutral → Outperform | $60 | +525.7% |
| Apr 30, 2026 | Initiated | Mizuho | Outperform | $50 | +421.4% |
| Apr 07, 2026 | Initiated | Leerink Partners | Outperform | $38 | +296.2% |
| Mar 24, 2026 | Upgrade | Wells Fargo | Equal Weight → Overweight | $27 | +181.5% |
| Mar 24, 2026 | Upgrade | H.C. Wainwright | Neutral → Buy | $28 | +192.0% |
| Jan 20, 2026 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform | $23 | +139.8% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| WHWK | Whitehawk Therapeutics Inc | 181.16M |
| MGNX | Macrogenics Inc | 145.87M |
| KYNB | Kyntra Bio Inc | 14.54M |
| CRBP | Corbus Pharmaceuticals Holdings Inc | 70.27M |
| PYXS | Pyxis Oncology Inc | 188.98M |
| ZYME | Zymeworks BC Inc | 1.84B |
| BCYC | Bicycle Therapeutics Plc ADR | 174.43M |
| CTMX | CytomX Therapeutics Inc | 444.73M |
| ADAG | Adagene Inc ADR | 134.28M |
| VRXA | Veraxa Biotech AG | 169.89M |
Insider trading
12 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Sep 18 '26 | Option Exercise | 0.00 | 3,750 | 0 | 13,712 | Sep 22 04:09 PM |
| Chow Gregory K. | CFO | Jun 02 '26 | Option Exercise | 0.00 | 2,500 | 0 | 4,725 | Jun 02 04:16 PM |
| Pauling David | Chief Admin. Ofcr. & GC | Mar 04 '26 | Option Exercise | 0.00 | 675 | 0 | 10,025 | Mar 06 04:25 PM |
| Chung Jane | Chief Executive Officer | Mar 04 '26 | Option Exercise | 0.00 | 788 | 0 | 21,567 | Mar 06 04:21 PM |
| Pauling David | Chief Admin. Ofcr. & GC | Mar 02 '26 | Option Exercise | 0.00 | 2,356 | 0 | 10,320 | Mar 03 06:59 PM |
| Pauling David | Chief Admin. Ofcr. & GC | Mar 01 '26 | Option Exercise | 0.00 | 1,342 | 0 | 8,515 | Mar 03 06:59 PM |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Mar 02 '26 | Option Exercise | 0.00 | 2,843 | 0 | 10,688 | Mar 03 06:56 PM |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Mar 01 '26 | Option Exercise | 0.00 | 1,125 | 0 | 8,308 | Mar 03 06:56 PM |
| Chung Jane | Chief Executive Officer | Mar 02 '26 | Option Exercise | 0.00 | 7,750 | 0 | 23,558 | Mar 03 06:48 PM |
| Chung Jane | Chief Executive Officer | Mar 01 '26 | Option Exercise | 0.00 | 3,188 | 0 | 17,079 | Mar 03 06:48 PM |
| BARBARA LEYMAN | Former Officer | Jan 20 '26 | Proposed Sale | 14.67 | 8,929 | 130,962 | Jan 20 04:17 PM | |
| Chung Jane | Chief Executive Officer | Dec 12 '25 | Option Exercise | 0.00 | 2,500 | 0 | 14,785 | Dec 16 08:47 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| FESM | Fidelity Enhanced Small Cap Core ETF | AUM: 6.90B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
| VFMO | Vanguard U.S. Momentum Factor ETF | AUM: 1.88B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | AUM: 96.50B |
News
latest 14 of 200- Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) -6.53%
- Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
- Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors (GlobeNewswire) -6.50%
- Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference (GlobeNewswire) -6.94%
- Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development (GlobeNewswire)
- STRO Stock Plummets 15% What Drove The Selloff? (Stocktwits) -14.94%
- Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study (GlobeNewswire)
- SpaceX upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly) +5.09%
- Barclays initiates oncology-focused biotechs with positive outlook (Investing.com)
- Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
- Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls (The Fly)
- Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 (GlobeNewswire)
- Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last? (Quartz) +5.21%
- Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls (The Fly) +7.35%
Quarterly earnings
2026Q3 EPS -1.900 missed -1.641, from -6.700 a year earlier. Sales 9.10 missed 14.10, from 9.69 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-12 16:30 | -1.900 | -1.641 | -1.899 | 9.10 | 14.10 | EPS +15.8% · sales -35.5% | vs 2025Q3, year-ago quarter · EPS -71.6% · sales -6.1% | 14 EPS · 12 sales | - |
| 2026Q2ended 2026-06-30 | 2026-08-12 08:30 | -2.330 | -2.194 | -2.325 | 9.84 | 11.96 | EPS +6.2% · sales -17.7% | vs 2025Q2, year-ago quarter · EPS +66.4% · sales -84.6% | 14 EPS · 12 sales | Open -5.79% vs SPY +0.54%. Close -14.94% vs SPY +0.25% |
| 2026Q1ended 2026-03-31 | 2026-05-14 16:30 | -2.940 | -2.736 | -2.942 | 14.52 | 8.89 | EPS +7.4% · sales +63.3% | vs 2025Q1, year-ago quarter · EPS -67.7% · sales -16.5% | 11 EPS · 10 sales | Open +14.13% vs SPY -0.85%. Close +1.43% vs SPY -1.20% |
| 2025Q4ended 2025-12-31 | 2026-03-23 16:30 | -5.290 | -8.163 | -5.447 | 11.65 | 9.26 | EPS -35.2% · sales +25.8% | vs 2024Q4, year-ago quarter · EPS -36.3% · sales -21.3% | 10 EPS · 9 sales | Open +8.81% vs SPY -0.62%. Close +10.50% vs SPY -0.34% |
| 2025Q3ended 2025-09-30 | 2025-11-06 16:30 | -6.700 | -3.945 | -6.699 | 9.69 | 10.14 | EPS +69.9% · sales -4.4% | vs 2024Q3, year-ago quarter · EPS +13.6% · sales +13.8% | 10 EPS · 9 sales | Open -4.48% vs SPY -0.36%. Close -13.36% vs SPY +0.10% |
| 2025Q2ended 2025-06-30 | 2025-08-07 16:30 | -1.400 | -3.824 | -1.360 | 63.75 | 15.84 | EPS -63.4% · sales +302.5% | vs 2024Q2, year-ago quarter · EPS -76.3% · sales +148.0% | 10 EPS · 9 sales | Open +0.52% vs SPY +0.29%. Close +0.30% vs SPY +0.78% |
| 2025Q1ended 2025-03-31 | 2025-05-08 16:30 | -9.100 | -6.426 | -9.141 | 17.40 | 11.61 | EPS +41.6% · sales +49.8% | vs 2024Q1, year-ago quarter · EPS -4.2% · sales +33.8% | 9 | Open +4.35% vs SPY +0.25%. Close -9.06% vs SPY -0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-13 16:30 | -8.300 | -8.304 | -8.778 | 14.80 | 12.15 | EPS 0.0% · sales +21.8% | vs 2023Q4, year-ago quarter · EPS -259.6% · sales -87.0% | 11 | Open -20.08% vs SPY +0.85%. Close -35.19% vs SPY +2.07% |
| 2024Q3ended 2024-09-30 | 2024-11-13 16:30 | -5.900 | -7.346 | -5.947 | 8.52 | 15.29 | EPS -19.7% · sales -44.3% | vs 2023Q3, year-ago quarter · EPS -27.2% · sales -49.7% | 11 | Open -1.77% vs SPY +0.02%. Close -12.88% vs SPY -0.64% |
| 2024Q2ended 2024-06-30 | 2024-08-13 16:30 | -5.900 | -7.916 | -5.912 | 25.71 | 21.02 | EPS -25.5% · sales +22.3% | vs 2023Q2, year-ago quarter · EPS -7.8% · sales +146.9% | 10 | Open +10.25% vs SPY +0.15%. Close +11.49% vs SPY +0.32% |
| 2024Q1ended 2024-03-31 | 2024-05-13 16:30 | -9.500 | -9.216 | -9.472 | 13.01 | 12.07 | EPS +3.1% · sales +7.7% | vs 2023Q1, year-ago quarter · EPS +11.8% · sales +2.6% | 10 | Open -0.24% vs SPY +0.04%. Close +2.60% vs SPY +0.46% |
| 2023Q4ended 2023-12-31 | 2024-03-26 08:30 | 5.200 | -2.713 | 5.092 | 113.73 | 57.36 | EPS -291.7% · sales +98.3% | vs 2022Q4, year-ago quarter · EPS -188.1% · sales +1219.1% | 9 | Open +17.43% vs SPY +0.28%. Close +27.83% vs SPY -0.18% |
| 2023Q3ended 2023-09-30 | 2023-11-13 16:30 | -8.100 | -7.360 | -8.133 | 16.92 | 13.01 | EPS +10.1% · sales +30.1% | vs 2022Q3, year-ago quarter · EPS +118.9% · sales -32.7% | 10 | - |
| 2023Q2ended 2023-06-30 | 2023-08-10 16:30 | -6.400 | -7.325 | -6.385 | 10.41 | 12.56 | EPS -12.6% · sales -17.1% | vs 2022Q2, year-ago quarter · EPS +16.4% · sales -62.9% | 8 | - |
| 2023Q1ended 2023-03-31 | 2023-05-15 08:30 | -8.500 | -7.837 | -8.523 | 12.67 | 12.13 | EPS +8.5% · sales +4.5% | vs 2022Q1, year-ago quarter · EPS +1.2% · sales +114.9% | 8 | - |
| 2022Q4ended 2022-12-31 | 2023-03-30 16:30 | -5.900 | -6.212 | -6.092 | 8.62 | 14.52 | EPS -5.0% · sales -40.6% | vs 2021Q4, year-ago quarter · EPS -28.9% · sales -17.5% | 8 | - |
Annual earnings
2025FY EPS -22.490 missed -17.807, from -29.600 a year earlier. Sales 102.48 beat 99.18, from 62.04 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -5.619 | - | - | 76.73 | - |
| 2029FYestimate | - | -6.086 | - | - | 40.20 | - |
| 2028FYestimate | - | -6.392 | - | - | 39.83 | - |
| 2027FYestimate | - | -6.330 | - | - | 35.06 | - |
| 2026FYestimate | - | -7.988 | - | - | 49.89 | - |
| 2025FY | -22.490 | -17.807 | -22.490 | 102.48 | 99.18 | - |
| 2024FY | -29.600 | -28.982 | -29.606 | 62.04 | 59.04 | - |
| 2023FY | -17.800 | -25.344 | -17.751 | 153.73 | 97.35 | - |
| 2022FY | -23.500 | -25.111 | -23.494 | 67.77 | 68.38 | - |
| 2021FY | -22.900 | -22.331 | -22.884 | 61.88 | 62.36 | - |
| 2020FY | -9.900 | 0.825 | -9.863 | 42.72 | 42.67 | 263.15 |
| 2019FY | -24.300 | -24.826 | -24.280 | 42.74 | 41.38 | - |
| 2018FY | -61.300 | -53.650 | -61.326 | 38.42 | 25.36 | - |
Quarterly results
2026Q3 revenue 9.10, from 9.69 a year earlier. Operating margin -241.1%, from -401.44% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026Q4 E -1.49 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026Q4 | E | per share | 2026-11-13 | -1.49 | -1.9% |
| 2026FY | R | per share | 2026-11-13 | -7.99 | +1.1% |
| 2026Q4 | R | per share | 2026-11-13 | -1.51 | -0.6% |
| 2026FY | S | per share | 2026-11-13 | 49.89 | -0.5% |
| 2026Q4 | S | per share | 2026-11-13 | 12.78 | +0.0% |
| 2026FY | E | per share | 2026-10-28 | -7.90 | 0.0% |
| 2026Q3 | E | per share | 2026-10-28 | -1.64 | 0.0% |
| 2026Q3 | R | per share | 2026-10-28 | -1.64 | 0.0% |
| 2026Q3 | S | per share | 2026-10-28 | 14.10 | 0.0% |
| 2026Q2 | E | per share | 2026-08-11 | -2.19 | 0.0% |
| 2026Q2 | R | per share | 2026-08-11 | -2.19 | 0.0% |
| 2026Q2 | S | per share | 2026-08-11 | 11.96 | 0.0% |
| 2026Q1 | E | per share | 2026-04-30 | -2.74 | 0.0% |
| 2026Q1 | R | per share | 2026-04-30 | -2.74 | 0.0% |
| 2026Q1 | S | per share | 2026-04-29 | 8.89 | -1.1% |
| 2025FY | E | per share | 2026-03-20 | -15.00 | -4.7% |
| 2025Q4 | E | per share | 2026-03-20 | -4.59 | +0.1% |
| 2025FY | R | per share | 2026-03-20 | -15.00 | -4.7% |
| 2025Q4 | R | per share | 2026-03-20 | -4.59 | +0.1% |
| 2025Q4 | S | per share | 2026-03-20 | 13.04 | +8.3% |
| 2025FY | S | - | 2026-03-20 | 101.29 | +0.4% |
| 2025Q3 | E | per share | 2025-10-26 | -0.39 | 0.0% |
| 2025Q3 | R | per share | 2025-10-26 | -0.39 | 0.0% |
| 2025Q3 | S | per share | 2025-10-22 | 10.14 | 0.0% |
| 2025Q2 | E | per share | 2025-08-02 | -0.38 | 0.0% |
| 2025Q2 | R | per share | 2025-08-02 | -0.38 | 0.0% |
| 2025Q2 | S | per share | 2025-08-02 | 15.84 | 0.0% |
| 2025Q1 | S | per share | 2025-04-29 | 11.61 | +0.0% |
| 2025Q1 | E | per share | 2025-03-14 | -0.64 | -24.7% |
| 2025Q1 | R | per share | 2025-03-14 | -0.64 | -24.7% |
| 2024FY | E | per share | 2025-03-03 | -2.90 | 0.0% |
| 2024FY | R | per share | 2025-03-03 | -2.90 | 0.0% |
| 2024Q4 | E | per share | 2025-02-01 | -0.83 | 0.0% |
| 2024Q4 | R | per share | 2025-02-01 | -0.83 | 0.0% |
| 2024Q4 | S | per share | 2025-02-01 | 12.15 | 0.0% |
| 2024FY | S | per share | 2025-01-29 | 59.04 | 0.0% |
| 2024Q3 | E | per share | 2024-10-30 | -0.73 | 0.0% |
| 2024Q3 | R | per share | 2024-10-30 | -0.73 | 0.0% |
| 2024Q3 | S | per share | 2024-10-30 | 15.29 | 0.0% |
| 2024Q2 | E | per share | 2024-08-06 | -0.79 | 0.0% |
| 2024Q2 | R | per share | 2024-08-06 | -0.79 | 0.0% |
| 2024Q2 | S | per share | 2024-08-06 | 21.02 | 0.0% |
| 2024Q1 | E | per share | 2024-05-08 | -0.92 | +0.7% |
| 2024Q1 | R | per share | 2024-05-08 | -0.92 | +0.7% |
| 2024Q1 | S | per share | 2024-05-08 | 12.07 | +1.3% |
| 2023FY | E | per share | 2024-03-25 | -2.53 | -13.7% |
| 2023FY | R | per share | 2024-03-25 | -2.53 | -13.7% |
| 2023FY | S | per share | 2024-03-25 | 97.35 | +52.4% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -8.617 | -61.326 | -24.28 | -9.863 | -22.884 | -23.494 | -17.751 | -29.606 | -22.487 | -12.6131 | - |
| Sales USD millions | 52 | 38 | 43 | 43 | 62 | 68 | 154 | 62 | 102 | 45 | - |
| Shares million shares | 2 | 2 | 2 | 5 | 5 | 6 | 6 | 8 | 9 | - | 17 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -5.947 | -8.778 | -9.141 | -1.36 | -6.699 | -5.447 | -2.942 | -2.325 | -1.899 |
| Sales USD millions | 9 | 15 | 17 | 64 | 10 | 12 | 15 | 10 | 9 |
| Shares million shares | 8 | 8 | 8 | 8 | 9 | 9 | 17 | 17 | - |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 45.11 | 102.48+65.2% | 62.04-59.6% | 153.73+126.8% | 67.77+9.5% | 61.88+44.9% | 42.720.0% | 42.74+11.2% | 38.42 |
| Cost of Goods Sold Incl. D&A | - | 7.32+1.4% | 7.22+5.9% | 6.82-17.7% | 8.29-15.1% | 9.77 | - | - | - |
| Gross Profit | - | 95.16+73.6% | 54.83-62.7% | 146.91+147.0% | 59.48+14.1% | 52.11 | - | - | - |
| Selling, General and Administrative Excl. Other | 155.84 | 200.11-31.8% | 293.28+24.2% | 236.19+25.3% | 188.43+25.1% | 150.63+37.6% | 109.48+17.2% | 93.43+31.4% | 71.10 |
| Research and Development | 128.39 | 166.42-34.0% | 252.04+39.7% | 180.43+31.5% | 137.17+31.4% | 104.40+35.7% | 76.96+17.3% | 65.61+20.9% | 54.26 |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -114.90 | -104.95 | -238.45 | -89.28 | -128.94 | -98.52 | -71.06 | -55.47 | -37.22 |
| Interest Expense | 39.03 | 38.21+2.1% | 37.43+169.9% | 13.87+314.0% | 3.35+6.7% | 3.14-23.0% | 4.08-6.2% | 4.35+171.9% | 1.60 |
| Unusual Expense | 4.65 | 53.41 | 0.00 | -9.92 | -12.13-372.6% | 4.45 | -41.50 | - | -0.84 |
| Net Income Before Taxes | -155.36 | -191.18 | -225.10 | -88.60 | -116.70 | -105.54 | -32.13 | -55.74 | -35.32 |
| Income Taxes | -0.10 | -0.09-103.8% | 2.36-87.0% | 18.19+627.6% | 2.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -155.27 | -191.09 | -227.46 | -106.79 | -119.20 | -105.54 | -32.13 | -55.74 | -35.32 |
| Net Income From Continuing Operations | -155.27 | -191.09 | -227.46 | -106.79 | -119.20 | -105.54 | -32.13 | -55.74 | -35.32 |
| Net Income | -155.27 | -191.09 | -227.46 | -106.79 | -119.20 | -105.54 | -32.13 | -55.74 | -35.32 |
| EPS (Recurring) per share | -9.17 | -18.09 | -29.61 | -18.90 | -25.17 | -22.21 | -18.78 | -24.28 | -61.33 |
| EPS (Basic, Before Extraordinaries) per share | -12.61 | -22.49 | -29.61 | -17.75 | -23.49 | -22.88 | -9.86 | -24.28 | -61.33 |
| EPS (Diluted) per share | -12.61 | -22.49 | -29.61 | -17.75 | -23.49 | -22.88 | -9.86 | -24.28 | -61.33 |
| EBITDA | - | -97.63 | -231.24 | -82.46 | -120.66 | -88.75 | -66.76 | -50.69 | -32.68 |
| Non-Operating Income (Expense) | 3.21 | 5.40-89.4% | 50.78+996.8% | 4.63+33.8% | 3.46+496.6% | 0.58-61.6% | 1.51-62.9% | 4.07+16.0% | 3.51 |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 11.07-43.2% | 19.50-0.9% | 19.68-5.3% | 20.78-10.6% | 23.24+95.0% | 11.92+15.6% | 10.31+259.2% | 2.87 |
| Price To Sales Ratio ratio | - | 0.96 | 2.28 | 1.68 | 6.05 | 11.09 | 16.55 | 5.91 | 1.35 |
| Gross Margin % | - | 92.85 | 88.37 | 95.57 | 87.77 | 84.21 | - | - | - |
| Operating Margin % | -254.72 | -102.41 | -384.34 | -58.07 | -190.26 | -159.22 | -166.32 | -129.79 | -96.89 |
| Net Margin % | -344.22 | -186.45 | -366.62 | -69.47 | -175.89 | -170.55 | -75.20 | -130.44 | -91.93 |
| Shares Outstanding million shares | - | 8.58+4.0% | 8.25+35.2% | 6.10+6.1% | 5.75+24.2% | 4.63+1.1% | 4.58+98.3% | 2.31+1.3% | 2.28 |
| Market Capitalization | 159.01 | 159.01+4.7% | 151.85-41.9% | 261.26-40.8% | 441.42-36.0% | 689.35-30.6% | 993.28+290.9% | 254.09+23.3% | 206.09 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 9.10-6.1% | 9.84-84.6% | 14.52-16.6% | 11.65-21.3% | 9.69+13.7% | 63.74+147.9% | 17.40+33.7% | 14.81-87.0% |
| Cost of Goods Sold Incl. D&A | - | 1.26-33.7% | 1.28-32.6% | 1.62-13.4% | 1.90+5.6% | 1.90+6.1% | 1.90+8.0% | 1.87+8.1% |
| Gross Profit | - | 8.58-86.1% | 13.24-14.6% | 10.02-22.6% | 7.79+15.9% | 61.84+158.5% | 15.50+37.8% | 12.94-88.4% |
| Selling, General and Administrative Excl. Other | 31.04-33.5% | 38.26-18.2% | 42.86-31.9% | 43.68-44.1% | 46.69-37.4% | 46.77-35.6% | 62.97-7.2% | 78.20+13.6% |
| Research and Development | 23.50-41.0% | 31.70-17.3% | 36.55-29.2% | 36.64-48.4% | 39.85-35.8% | 38.33-38.2% | 51.60-9.3% | 71.04+32.1% |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -21.94 | -29.69-296.9% | -29.61 | -33.66 | -38.90 | 15.08 | -47.47 | -65.26-251.2% |
| Interest Expense | 10.15+5.0% | 9.86+2.2% | 9.47+1.4% | 9.55+9.9% | 9.67+22.3% | 9.65+32.4% | 9.34+30.1% | 8.69+36.0% |
| Unusual Expense | 0.02-99.8% | 0.20-98.9% | 0.04-99.8% | 4.39 | 9.56 | 18.42 | 21.04 | 0.00 |
| Net Income Before Taxes | -31.49 | -38.53 | -38.50 | -46.84 | -56.86 | -11.52 | -75.97 | -70.09-249.5% |
| Income Taxes | 0.00 | 0.00 | -0.01 | -0.08-103.4% | 0.00 | -0.02-300.0% | 0.00 | 2.35-85.1% |
| Consolidated Net Income | -31.49 | -38.53 | -38.48 | -46.76 | -56.86 | -11.50 | -75.97 | -72.44-333.2% |
| Net Income From Continuing Operations | -31.49 | -38.53 | -38.48 | -46.76 | -56.86 | -11.50 | -75.97 | -72.44-333.2% |
| Net Income | -31.49 | -38.53 | -38.48 | -46.76 | -56.86 | -11.50 | -75.97 | -72.44-333.2% |
| EPS (Recurring) per share | -1.90 | -2.32-1464.7% | -2.94 | -5.09 | -5.91 | 0.17 | -7.37 | -8.78-309.5% |
| EPS (Basic, Before Extraordinaries) per share | -1.90 | -2.33 | -2.94 | -5.45 | -6.70 | -1.36 | -9.14 | -8.78-272.5% |
| EPS (Diluted) per share | -1.90 | -2.33 | -2.94 | -5.45 | -6.70 | -1.36 | -9.14 | -8.78-272.5% |
| EBITDA | - | -28.43-267.4% | -28.34 | -32.03 | -37.00 | 16.98 | -45.57 | -63.39-241.2% |
| Non-Operating Income (Expense) | 0.62-51.2% | 1.22-17.6% | 0.62-67.2% | 0.75-80.6% | 1.27-95.3% | 1.48-53.0% | 1.89+0.5% | 3.86+73.9% |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 1.59-61.8% | 1.23-77.8% | 1.31-71.9% | 1.55-76.3% | 4.16-14.6% | 5.54-8.7% | 4.67-5.1% |
| Price To Sales Ratio ratio | - | 12.04 | 3.27 | 0.97 | 0.70 | 0.58 | 0.81 | 2.45 |
| Gross Margin % | - | 87.17 | 91.20 | 86.06 | 80.40 | 97.02 | 89.08 | 87.39 |
| Operating Margin % | -241.15 | -301.73 | -203.91 | -288.98 | -401.33 | 23.65 | -272.84 | -440.66 |
| Net Margin % | -346.11 | -391.64 | -264.99 | -401.49 | -586.58 | -18.04 | -436.62 | -489.18 |
| Shares Outstanding million shares | - | 16.58+95.7% | 16.57+96.6% | 8.58+4.0% | 8.51+3.3% | 8.47+3.4% | 8.43+34.9% | 8.25+35.2% |
| Market Capitalization | 159.01+115.2% | 550.14+809.6% | 412.69+652.0% | 98.57-35.1% | 73.90-74.1% | 60.48-67.0% | 54.88-84.1% | 151.85-41.9% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 141.43-55.4% | 316.89-15.6% | 375.62+12.3% | 334.36+68.9% | 197.94-46.2% | 368.14+212.4% | 117.86-42.4% | 204.49+828.7% | 22.02 |
| Short Term Receivables | 3.98-53.8% | 8.62-76.1% | 36.08+406.7% | 7.12-42.8% | 12.45+123.9% | 5.56-11.7% | 6.30+153.0% | 2.49+53.7% | 1.62 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 5.52-69.0% | 17.80+80.7% | 9.85-15.6% | 11.67+43.7% | 8.12+80.8% | 4.49+1.8% | 4.41+49.0% | 2.96+48.7% | 1.99 |
| Total Current Assets | 150.93-56.0% | 343.31-18.6% | 421.54+19.4% | 353.15+61.6% | 218.51-42.2% | 378.18+194.1% | 128.57-38.8% | 209.95+719.2% | 25.63 |
| Net Property, Plant & Equipment | 21.55-39.9% | 35.87-19.9% | 44.76-12.3% | 51.06-1.0% | 51.59+298.7% | 12.94+34.4% | 9.63-11.9% | 10.93-21.9% | 14.00 |
| Total Investments and Advances | 0.860.0% | 0.86 | 0.00 | 0.00-100.0% | 69.65+7905.7% | 0.87-94.4% | 15.62+156100.0% | 0.010.0% | 0.01 |
| Long-Term Note Receivable | - | - | - | - | - | - | - | 0.00-100.0% | 0.21 |
| Intangible Assets | - | - | - | - | - | - | - | - | 0.00 |
| Other Assets | 0.49-93.2% | 7.17+61.5% | 4.44+62.6% | 2.73+64.5% | 1.66-21.7% | 2.12-16.5% | 2.54+13.4% | 2.24+98.2% | 1.13 |
| Total Assets | 173.83-55.1% | 387.21-17.7% | 470.74+15.7% | 406.94+19.2% | 341.41-13.4% | 394.11+152.0% | 156.37-29.9% | 223.14+444.5% | 40.98 |
| Short Term Debt Incl. Current Port. of LT Debt | 7.78+4.0% | 7.48-28.6% | 10.48-38.7% | 17.09+64.2% | 10.41 | 0.00-100.0% | 1.00-78.8% | 4.72-67.6% | 14.56 |
| Accounts Payable | 7.57-27.7% | 10.47+10.9% | 9.44+96.7% | 4.80-57.6% | 11.33+104.5% | 5.54-0.7% | 5.58+82.4% | 3.06+5.5% | 2.90 |
| Income Tax Payable | 0.00-100.0% | 0.02-99.9% | 15.16 | - | - | - | - | - | - |
| Other Current Liabilities | 59.78-47.5% | 113.92+94.2% | 58.66+31.3% | 44.66+123.3% | 20.00-16.8% | 24.05-8.8% | 26.38-7.9% | 28.64+97.7% | 14.49 |
| Total Current Liabilities | 75.13-43.0% | 131.89+40.7% | 93.75+40.9% | 66.55+59.4% | 41.74+41.0% | 29.60-10.2% | 32.97-9.5% | 36.42+14.0% | 31.96 |
| Long Term Debt | 227.43+15.8% | 196.48+14.1% | 172.27+416.7% | 33.34-29.0% | 46.96+91.3% | 24.55+176.5% | 8.88-11.2% | 10.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 3.72-73.9% | 14.23-74.2% | 55.07-38.8% | 90.00+59900.0% | 0.15-98.1% | 7.92-52.7% | 16.74-62.9% | 45.18+195.1% | 15.31 |
| Total Liabilities | 306.28-10.6% | 342.61+6.7% | 321.09+69.1% | 189.90+113.8% | 88.84+43.2% | 62.06+5.9% | 58.58-36.0% | 91.60+93.8% | 47.27 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 102.50 |
| Common Equity | -132.45-397.0% | 44.60-70.2% | 149.65-31.1% | 217.05-14.1% | 252.56-23.9% | 332.05+239.6% | 97.79-25.7% | 131.54 | -108.79 |
| Total Shareholders Equity | -132.45-397.0% | 44.60-70.2% | 149.65-31.1% | 217.05-14.1% | 252.56-23.9% | 332.05+239.6% | 97.79-25.7% | 131.54 | -6.29 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -132.45-397.0% | 44.60-70.2% | 149.65-31.1% | 217.05-14.1% | 252.56-23.9% | 332.05+239.6% | 97.79-25.7% | 131.54 | -6.29 |
| Total Liabilities & Stockholders Equity | 173.83-55.1% | 387.21-17.7% | 470.74+15.7% | 406.94+19.2% | 341.41-13.4% | 394.11+152.0% | 156.37-29.9% | 223.14+444.5% | 40.98 |
| Book Value Per Share per share | -15.43-385.7% | 5.40-78.0% | 24.53-35.0% | 37.75-30.8% | 54.52-24.9% | 72.58+71.5% | 42.33-26.5% | 57.57 | -47.62 |
| Tangible Book Value Per Share per share | -15.43-385.7% | 5.40-78.0% | 24.53-35.0% | 37.75-30.8% | 54.52-24.9% | 72.58+71.5% | 42.33-26.5% | 57.57 | -47.62 |
| Full-Time Employees people | 137-59.5% | 338+11.9% | 302+2.4% | 295+23.4% | 239+25.1% | 191+13.7% | 168+6.3% | 158+23.4% | 128 |
| Price to Book Ratio ratio | -1.54 | 3.40 | 2.33 | 1.92 | 2.73 | 2.99 | 2.60 | 1.57 | -1.40 |
| Return on Assets % | -68.12 | -53.02 | -24.34 | -31.86 | -28.70 | -11.67 | -29.38 | -26.74 | -35.65 |
| Return on Equity % | - | -234.19 | -58.25 | -50.77 | -36.11 | -14.95 | -48.62 | -56.39 | -712.95 |
| Return on Invested Capital % | -201.20 | -94.35 | -33.17 | -47.61 | -35.24 | -9.01 | -52.26 | -24.95 | - |
| Quick Ratio ratio | 2.01 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 |
| Current Ratio ratio | 2.01 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | -191.09 | -227.46 | -106.79 | -119.20 | -105.54 | -32.13 | -55.74 | -35.32 |
| Depreciation | - | 7.32+1.4% | 7.22+5.9% | 6.82-17.7% | 8.29-15.1% | 9.77+127.2% | 4.30-10.0% | 4.78+5.3% | 4.54 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | - | 56.93+187.5% | 19.80-12.9% | 22.74+126.0% | 10.06-68.3% | 31.71 | -28.48-409.2% | 9.21+983.5% | 0.85 |
| Funds from Operations | - | -126.83 | -200.44 | -77.24 | -100.86 | -64.06 | -56.32 | -41.76 | -29.92 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -50.40-666.3% | 8.90 | -34.38-132.9% | 104.41 | -17.62 | -11.49 | -23.26-154.6% | 42.61 |
| Cash from Operating Activities | - | -177.23 | -191.54 | -111.62-3244.2% | 3.55 | -81.68 | -67.80 | -65.02-612.8% | 12.68 |
| Capital Expenditures | - | -1.70 | -3.10 | -4.32 | -7.86 | -15.32 | -7.13 | -3.48 | -1.56 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | - | 46.71-78.9% | 221.61+56723.1% | 0.39 | -27.17 | -82.00-1173.3% | 7.64 | -47.65 | -78.71 |
| Purchase of Investments | - | -264.95 | -461.52 | -460.30 | -216.67 | -248.73 | -130.74 | -196.23 | -81.46 |
| Sale Or Maturity of Investments | - | 311.66-54.4% | 683.13+48.3% | 460.69+143.1% | 189.50+13.7% | 166.73+20.5% | 138.38-6.9% | 148.58+5302.9% | 2.75 |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00-100.0% | 0.010.0% | 0.01-88.9% | 0.09 | 0.00-100.0% | 0.08 |
| Cash from Investing Activities | - | 45.01-79.4% | 218.51 | -3.92 | -35.02 | -97.31-16318.3% | 0.60 | -51.13 | -80.19 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | 0.38-99.6% | 98.65+587.9% | 14.34-75.3% | 58.15+1268.2% | 4.25-98.3% | 254.56+22833.3% | 1.11-99.3% | 169.58 |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | 0.38-99.6% | 98.65+587.9% | 14.34-75.3% | 58.15+1268.2% | 4.25-98.3% | 254.56+22833.3% | 1.11-99.3% | 169.58 |
| Proceedsfrom Stock Options | - | 0.37-99.6% | 98.38+601.7% | 14.02-75.8% | 57.88+3188.6% | 1.76-99.3% | 252.70+27072.0% | 0.93-99.5% | 169.18 |
| Issuance or Reduction of Debt, Net | - | 0.00 | -4.08-103.3% | 123.71 | -9.38 | 0.00-100.0% | 15.00 | -5.00 | 0.00 |
| Change in Long Term Debt | - | 0.00 | -4.08-103.3% | 123.71 | -9.38 | 0.00-100.0% | 15.00 | -5.00 | 0.00 |
| Issuance of Long Term Debt | - | 0.00 | 0.00-100.0% | 136.21 | 0.00 | 0.00-100.0% | 25.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | -4.08 | -12.50 | -9.38 | 0.00 | -10.00 | -5.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | -0.33 | -0.51 | -0.49 | -0.46 | -0.99 | -0.31 | -0.30-124.8% | 1.21 |
| Other Financing Activities Uses | - | -0.33 | -0.51 | -0.49 | -0.46 | -0.99 | -0.31 | -0.30 | 0.00 |
| Cash from Financing Activities | - | 0.04-100.0% | 94.05-31.6% | 137.55+184.7% | 48.31+1381.9% | 3.26-98.8% | 269.25 | -4.18-102.4% | 170.78 |
| Net Change in Cash | - | -132.17-209.2% | 121.02+449.8% | 22.01+30.7% | 16.84 | -175.74-187.0% | 202.05 | -120.34-216.5% | 103.28 |
| Free Cash Flow | - | -178.93 | -194.64 | -115.93 | -4.31 | -97.00 | -74.93 | -68.50-715.5% | 11.13 |
| Price to Free Cash Flow ratio | - | - | - | - | - | - | - | - | 4.67 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 142.18-15.2% | 164.35-19.9% | 202.56-18.6% | 141.43-55.4% | 167.59-56.8% | 205.13-51.8% | 248.97-20.5% | 316.89-15.6% |
| Short Term Receivables | 12.81+226.8% | 5.80-27.5% | 12.48-8.0% | 3.98-53.8% | 3.92-41.1% | 8.00+15.1% | 13.56-56.7% | 8.62-76.1% |
| Inventories | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | - | 5.50-70.3% | 5.93-76.2% | 5.52-69.0% | 10.60-2.5% | 18.50+75.7% | 24.88+147.3% | 17.80+80.7% |
| Total Current Assets | 154.99-14.9% | 175.65-24.2% | 220.97-23.1% | 150.93-56.0% | 182.11-55.1% | 231.63-47.8% | 287.41-18.9% | 343.31-18.6% |
| Net Property, Plant & Equipment | 14.31-46.4% | 16.82-43.6% | 19.07-42.4% | 21.55-39.9% | 26.69-29.8% | 29.82-25.0% | 33.08-21.6% | 35.87-19.9% |
| Total Investments and Advances | - | 0.860.0% | 0.860.0% | 0.860.0% | 0.860.0% | 0.860.0% | 0.860.0% | 0.86 |
| Intangible Assets | - | - | - | - | 0.00 | - | - | - |
| Other Assets | 7.35 | 1.13+2160.0% | 1.09+1111.1% | 0.49-93.2% | 0.00-100.0% | 0.05-99.0% | 0.09-98.4% | 7.17+61.5% |
| Total Assets | 176.65-15.7% | 194.46-25.9% | 241.99-24.7% | 173.83-55.1% | 209.66-53.6% | 262.36-46.4% | 321.43-20.3% | 387.21-17.7% |
| Short Term Debt Incl. Current Port. of LT Debt | - | 6.66-17.4% | 7.60-2.1% | 7.78+4.0% | 7.96+10.6% | 8.06+16.3% | 7.76+16.3% | 7.48-28.6% |
| Accounts Payable | - | 3.36-22.0% | 5.49-32.9% | 7.57-27.7% | 7.03+13.0% | 4.31-29.2% | 8.18+8.9% | 10.47+10.9% |
| Income Tax Payable | - | - | - | 0.00-100.0% | - | - | - | 0.02-99.9% |
| Other Current Liabilities | 40.12-29.5% | 42.88-30.7% | 57.73-50.7% | 59.78-47.5% | 56.90-51.7% | 61.88-47.1% | 117.10+133.5% | 113.92+94.2% |
| Total Current Liabilities | 40.12-44.2% | 52.90-28.8% | 70.81-46.8% | 75.13-43.0% | 71.89-45.2% | 74.25-42.9% | 133.05+67.3% | 131.89+40.7% |
| Long Term Debt | 259.01+18.0% | 243.19+14.9% | 235.14+15.3% | 227.43+15.8% | 219.58+15.8% | 211.62+15.3% | 203.93+14.7% | 196.48+14.1% |
| Provision for Risks Charges | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 10.05+84.4% | 1.69-80.3% | 2.93-71.4% | 3.72-73.9% | 5.45-72.3% | 8.60-63.2% | 10.26-78.6% | 14.23-74.2% |
| Total Liabilities | 309.18+4.1% | 297.78+1.1% | 308.88-11.0% | 306.28-10.6% | 296.93-12.8% | 294.47-12.6% | 347.24+13.7% | 342.61+6.7% |
| Non-Equity Reserves | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -132.54 | -103.32 | -66.89 | -132.45-397.0% | -87.27-178.5% | -32.11-121.1% | -25.81-126.3% | 44.60-70.2% |
| Total Shareholders Equity | -132.54 | -103.32 | -66.89 | -132.45-397.0% | -87.27-178.5% | -32.11-121.1% | -25.81-126.3% | 44.60-70.2% |
| Accumulated Minority Interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -132.54 | -103.32 | -66.89 | -132.45-397.0% | -87.27-178.5% | -32.11-121.1% | -25.81-126.3% | 44.60-70.2% |
| Total Liabilities & Stockholders Equity | 176.65-15.7% | 194.46-25.9% | 241.99-24.7% | 173.83-55.1% | 209.66-53.6% | 262.36-46.4% | 321.43-20.3% | 387.21-17.7% |
| Book Value Per Share per share | - | -6.23 | -4.04 | -15.43-385.7% | -10.25-175.9% | -3.79-120.4% | -3.06-119.5% | 5.40-78.0% |
| Tangible Book Value Per Share per share | - | -6.23 | -4.04 | -15.43-385.7% | -10.25-175.9% | -3.79-120.4% | -3.06-119.5% | 5.40-78.0% |
| Full-Time Employees people | - | 128-47.5% | - | 137-59.5% | 178 | 244 | 269 | 338+11.9% |
| Price to Book Ratio ratio | -1.54 | -8.22 | -1.61 | -1.13 | -0.85 | -1.88 | -2.13 | 3.40 |
| Return on Assets % | -80.39 | -79.08 | -54.53 | -68.12 | -65.54 | -55.55 | -67.66 | -53.02 |
| Return on Equity % | - | - | - | - | -1,810.01 | -347.64 | -679.15 | -234.19 |
| Return on Invested Capital % | -24.90 | -27.55 | -22.87 | -49.24 | -42.97 | -6.41 | -42.65 | -30.05 |
| Quick Ratio ratio | - | 3.32 | 3.12 | 2.01 | 2.53 | 3.12 | 2.16 | 2.60 |
| Current Ratio ratio | 3.86 | 3.32 | 3.12 | 2.01 | 2.53 | 3.12 | 2.16 | 2.60 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | - | -38.53 | -38.48 | -46.76 | -56.86 | -11.50 | -75.97 | -72.44-333.2% |
| Depreciation | - | 1.26-33.7% | 1.28-32.6% | 1.62-13.4% | 1.90+5.6% | 1.90+6.1% | 1.90+8.0% | 1.87+8.1% |
| Other Funds (Non Cash) | - | 12.76-17.5% | 11.89-22.4% | 14.02-3.8% | 12.12 | 15.46+111.5% | 15.33+84.0% | 14.57+409.4% |
| Funds from Operations | - | -24.52-518.4% | -25.32 | -31.11 | -42.84 | 5.86 | -58.74 | -56.00-257.1% |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -13.78 | -16.94 | 4.68 | 4.65 | -50.58-204.6% | -9.15 | -15.73 |
| Cash from Operating Activities | - | -38.29 | -42.26 | -26.43 | -38.19 | -44.72-572.7% | -67.88 | -71.74-609.9% |
| Capital Expenditures | - | 0.00 | -0.01 | -0.18 | -0.25 | -0.09 | -1.17 | -1.07 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | - | 19.36+625.1% | -45.25 | 18.89-78.7% | 40.24-72.8% | 2.67 | -15.08-123.4% | 88.56 |
| Purchase of Investments | - | -27.85 | -124.70 | -4.04 | -89.94 | -28.59 | -142.38 | -126.03 |
| Sale Or Maturity of Investments | - | 47.21+51.0% | 79.45-37.6% | 22.93-89.3% | 130.18-31.9% | 31.26-59.8% | 127.30-36.2% | 214.59+266.8% |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | - | 19.36+650.4% | -45.26 | 18.70-78.6% | 39.99-72.8% | 2.58 | -16.26-125.4% | 87.49 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | -0.42 | 103.23+41192.0% | 0.00 | 0.13-88.1% | 0.00-100.0% | 0.25-75.7% | 0.00 |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | -0.42 | 103.23+41192.0% | 0.00 | 0.13-88.1% | 0.00-100.0% | 0.25-75.7% | 0.00 |
| Proceedsfrom Stock Options | - | -0.47 | 103.13+41152.0% | 0.00 | 0.13-86.2% | 0.00-100.0% | 0.25-72.5% | 0.00 |
| Issuance or Reduction of Debt, Net | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Change in Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Issuance of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | 0.00 | -0.16 | -0.07 | -0.03 | -0.06 | -0.18 | -0.02 |
| Other Financing Activities Uses | - | 0.00 | -0.16 | -0.07 | -0.03 | -0.06 | -0.18 | -0.02 |
| Cash from Financing Activities | - | -0.42 | 103.08+147157.1% | -0.06 | 0.10-90.2% | -0.06-100.1% | 0.07 | -0.02 |
| Net Change in Cash | - | -19.35 | 15.55 | -7.80-149.6% | 1.90-97.7% | -42.20-265.0% | -84.08 | 15.73 |
| Free Cash Flow | - | -38.29 | -42.27 | -26.62 | -38.44 | -44.81-615.1% | -69.06 | -72.81-676.5% |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Total Biological Products, (No Diagnostic Substances) revenue | 62.04 | 102.48 | +65.2% | 100.0% |
| Total | 62.04 | 102.48 | +65.2% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 62.04 | 102.48 | +65.2% | 100.0% |
| Total | 62.04 | 102.48 | +65.2% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 15.71% | 2.3M | 14.4M | 310.94K |
| 2026-10-15 | 13.65% | 2.0M | 14.4M | 297.75K |
| 2026-09-30 | 12.86% | 1.8M | 14.4M | 306.43K |
| 2026-09-15 | 14.45% | 2.1M | 14.4M | 355.36K |
| 2026-08-31 | 12.59% | 1.8M | 14.4M | 336.21K |
| 2026-08-14 | 12.91% | 1.9M | 14.4M | 370.91K |
| 2026-07-31 | 12.20% | 1.7M | 14.3M | 349.14K |
| 2026-07-15 | 11.56% | 1.7M | 14.3M | 346.36K |
| 2026-06-30 | 9.53% | 1.4M | 14.3M | 324.71K |
| 2026-06-15 | 6.45% | 0.9M | 14.3M | 268.34K |
| 2026-05-29 | 5.26% | 0.8M | 14.3M | 258.00K |
| 2026-05-15 | 8.35% | 1.2M | 14.3M | 211.26K |
| 2026-04-30 | 6.13% | 1.0M | 15.9M | 200.32K |
| 2026-04-15 | 4.70% | 0.7M | 15.9M | 177.01K |
| 2026-03-31 | 4.17% | 0.6M | 15.4M | 155.74K |
| 2026-03-13 | 3.51% | 0.5M | 15.2M | 131.16K |
| 2026-02-27 | 3.41% | 0.5M | 15.2M | 127.12K |
| 2026-02-13 | 4.25% | 0.6M | 15.2M | 120.99K |
| 2026-01-30 | 7.50% | 0.6M | 7.9M | 110.84K |
| 2026-01-15 | 6.70% | 0.5M | 7.9M | 132.81K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 7.50 | 0.20 | 4.90 | 0.00 | 800.4% | 0.00 | 0.00 | 0.879 | -0.030 | 0.003 |
| call | 10.00 | 0.00 | 4.90 | 0.65 | 965.8% | 40.00 | 0.00 | 0.745 | -0.271 | 0.005 |
| call | 12.50 | 0.00 | 4.90 | 0.45 | 1074.5% | 729 | 0.00 | 0.732 | -0.318 | 0.005 |
| call | 15.00 | 0.00 | 0.45 | 0.30 | 1107.5% | 3.00 | 0.00 | 0.717 | -0.342 | 0.005 |
| call | 17.50 | 0.00 | 4.90 | 0.00 | 367.2% | 0.00 | 0.00 | 0.198 | -0.091 | 0.004 |
| call | 20.00 | 0.00 | 2.00 | 0.45 | 1222.7% | 18.00 | 0.00 | 0.701 | -0.388 | 0.005 |
| call | 22.50 | 0.00 | 4.90 | 1.05 | 457.5% | 5.00 | 0.00 | 0.173 | -0.104 | 0.004 |
| call | 25.00 | 0.00 | 4.90 | 9.00 | 482.7% | 0.00 | 0.00 | 0.165 | -0.106 | 0.004 |
| call | 30.00 | 0.00 | 0.70 | 1.52 | 488.4% | 8.00 | 0.00 | 0.151 | -0.103 | 0.004 |
| call | 35.00 | 0.00 | 4.90 | 11.70 | 576.8% | 8.00 | 0.00 | 0.146 | -0.118 | 0.003 |
| call | 40.00 | 0.00 | 4.90 | 1.00 | 633.1% | 6.00 | 0.00 | 0.141 | -0.127 | 0.003 |
| call | 45.00 | 0.00 | 4.90 | 10.24 | 648.2% | 5.00 | 0.00 | 0.136 | -0.127 | 0.003 |
| call | 50.00 | 0.00 | 4.90 | 0.00 | 677.0% | 0.00 | 0.00 | 0.132 | -0.130 | 0.003 |
| call | 55.00 | 0.00 | 4.90 | 0.00 | 702.5% | 0.00 | 0.00 | 0.130 | -0.133 | 0.003 |
| call | 60.00 | 0.00 | 4.90 | 0.00 | 725.4% | 0.00 | 0.00 | 0.127 | -0.136 | 0.003 |
| put | 7.50 | 0.00 | 0.15 | 0.10 | 157.2% | 42.00 | 57.00 | -0.124 | -0.029 | 0.003 |
| put | 10.00 | 0.00 | 4.90 | 0.00 | 877.6% | 0.00 | 0.00 | -0.255 | -0.270 | 0.005 |
| put | 12.50 | 0.50 | 4.90 | 4.00 | 518.2% | 2.00 | 0.00 | -0.268 | -0.316 | 0.005 |
| put | 15.00 | 3.10 | 7.90 | 5.80 | 697.0% | 0.00 | 1.00 | -0.778 | -0.081 | 0.004 |
| put | 17.50 | 5.50 | 10.20 | 2.75 | 729.6% | 0.00 | 0.00 | -0.802 | -0.090 | 0.004 |
| put | 20.00 | 8.00 | 12.90 | 3.75 | 821.2% | 0.00 | 0.00 | -0.817 | -0.097 | 0.004 |
| put | 22.50 | 10.50 | 15.20 | 0.00 | 831.8% | 0.00 | 0.00 | -0.827 | -0.102 | 0.004 |
| put | 25.00 | 13.00 | 17.70 | 7.65 | 871.9% | 0.00 | 0.00 | -0.835 | -0.106 | 0.003 |
| put | 30.00 | 18.00 | 22.70 | 8.30 | 938.2% | 0.00 | 0.00 | -0.846 | -0.113 | 0.003 |
| put | 35.00 | 23.00 | 27.70 | 0.00 | 991.7% | 0.00 | 0.00 | -0.853 | -0.118 | 0.003 |
| put | 40.00 | 28.00 | 32.70 | 0.00 | 1036.6% | 0.00 | 0.00 | -0.859 | -0.123 | 0.003 |
| put | 45.00 | 33.00 | 37.70 | 0.00 | 1074.7% | 0.00 | 0.00 | -0.863 | -0.126 | 0.003 |
| put | 50.00 | 38.00 | 42.70 | 27.40 | 1108.5% | 0.00 | 0.00 | -0.866 | -0.129 | 0.003 |
| put | 55.00 | 43.00 | 47.70 | 0.00 | 1138.0% | 0.00 | 0.00 | -0.869 | -0.131 | 0.003 |
| put | 60.00 | 48.00 | 52.70 | 0.00 | 1164.8% | 0.00 | 0.00 | -0.872 | -0.133 | 0.003 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-12 | 8-K | Current report | 2026-11-12 | SEC |
| 2026-11-09 | SCHEDULE 13G | SEC | ||
| 2026-09-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-18 | SEC |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-12 | 8-K | Current report | 2026-08-12 | SEC |
| 2026-07-30 | SCHEDULE 13G | SEC | ||
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-05 | SEC |
| 2026-06-08 | 8-K | Current report | 2026-06-05 | SEC |
| 2026-06-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-02 | SEC |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-15 | SCHEDULE 13G | SEC | ||
| 2026-05-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-14 | 8-K | Current report | 2026-05-14 | SEC |
| 2026-05-14 | SCHEDULE 13G/A | SEC | ||
| 2026-05-01 | SCHEDULE 13G | SEC | ||
| 2026-04-22 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-04-22 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-05 | SEC |
| 2026-04-22 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-04-21 | SCHEDULE 13G | SEC | ||
| 2026-04-21 | SCHEDULE 13G/A | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| PERCEPTIVE ADVISORS LLC | 7.87% |
| BVF INC/IL | 7.55% |
| Affinity Asset Advisors, LLC | 7.08% |
| BlackRock, Inc. | 6.78% |
| Samsara BioCapital, LLC | 6.41% |
| Kynam Capital Management, LP | 5.27% |
| ORBIMED ADVISORS LLC | 4.49% |
| BALYASNY ASSET MANAGEMENT L.P. | 4.29% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.19% |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.53% |
Funds
| Fund | % owned |
|---|---|
| Eventide Healthcare & Life Sciences Fund | 3.53% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.03% |
| iShares Russell 2000 ETF | 1.97% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.07% |
| Fidelity Small Cap Index Fund | 1.05% |
| Nuveen Quant Small Cap Equity Fund | 0.76% |
| iShares Russell 2000 Value ETF | 0.59% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.55% |
| Goldman Sachs Small Cap Equity Insights Fund | 0.47% |
| VANGUARD U.S. MOMENTUM FACTOR ETF | 0.42% |
OakChart. STRO. Cached 15 minutes. Terms